Structure-based and ligand-based drug design for HER 2 receptor. - Wikidata - wikimedia - TriplyDB

Structure-based and ligand-based drug design for HER 2 receptor.

Structure-based and ligand-based drug design for HER 2 receptor.

http://www.wikidata.org/entity/Q43061745

about

TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico Identification of potent EGFR inhibitors from TCM Database@Taiwan Identifying HER2 inhibitors from natural products database Screening from the world's largest TCM database against H1N1 virus.Structure and stability analysis of cytotoxic complex of camel α-lactalbumin and unsaturated fatty acids produced at high temperature.High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan.Investigation of anti-infection mechanism of lactoferricin and splunc-1.Potential retinoid x receptor agonists for treating Alzheimer's disease from traditional chinese medicine.In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.Lead Screening for HIV of C-C Chemokine Receptor Type 5 Receptor Inhibited by Traditional Chinese Medicine.In Silico Investigation of Cytochrome P450 2C9 in relation to Aging Using Traditional Chinese Medicine.Treatment of acute lymphoblastic leukemia from traditional chinese medicine Lead Screening for Chronic Obstructive Pulmonary Disease of IKK2 Inhibited by Traditional Chinese Medicine Lead screening for CXCR4 of the human HIV infection receptor inhibited by traditional Chinese medicine Lead screening for HIV-1 integrase (IN) inhibited by traditional Chinese medicine.In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening.Insight into HIV of IFN-induced myxovirus resistance 2 (MX2) expressed by traditional Chinese medicine In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.An investigation of small GTPases in relation to liver tumorigenesis using traditional Chinese medicine.Investigation of estrogen receptor (ESR1) for breast cancer from traditional Chinese medicine First principles calculations of thermodynamics and kinetic parameters and molecular dynamics simulations of acetylcholinesterase reactivators: can mouse data provide new insights into humans?Retrieving novel C5aR antagonists using a hybrid ligand-based virtual screening protocol based on SVM classification and pharmacophore models.A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods.Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.Comparative Proteomics Reveals that Phosphorylation of β Carbonic Anhydrase 1 Might be Important for Adaptation to Drought Stress in Brassica napus.Protein-protein interactions: principles, techniques, and their potential role in new drug development.In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase.Biological evaluation and interaction of a newly designed anti-cancer Pd(II) complex and human serum albumin.Molecular modeling studies of Yersinia pestis dihydrofolate reductase.Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase.Search for novel remedies to augment radiation resistance of inhabitants of Fukushima and Chernobyl disasters: identifying DNA repair protein XRCC4 inhibitors.Molecular modeling of Mycobacterium tuberculosis dUTpase: docking and catalytic mechanism studies.A possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitors.Insight into the inhibitory mechanism and binding mode between D77 and HIV-1 integrase by molecular modeling methods.Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?In silico pharmacology suggests ginger extracts may reduce stroke risks.Design of new chemotherapeutics against the deadly anthrax disease. Docking and molecular dynamics studies of inhibitors containing pyrrolidine and riboamidrazone rings on nucleoside hydrolase from Bacillus anthracis.Traditional Chinese medicine as dual guardians against hypertension and cancer?Investigation into potent inflammation inhibitors from traditional Chinese medicine.

P2860

Q28476702-B7DD2620-890F-4B7C-A5C8-039698DD0924 Q28477481-341B14A9-5590-4E40-870A-66F9992E54C7 Q28478359-85943F9F-4BC9-4A68-A874-E28D54EBB288 Q30399346-39E64793-4F4F-497A-B8F3-2D5F4CBE95F8 Q30401575-015F17F1-EB02-43D8-AE48-3637973AC880 Q30408391-705AED5B-E907-4C3D-8253-BBF7270F2D6E Q33614360-480DB62F-5424-488B-8AA7-65140A82D80B Q33614602-E34F0E2F-12CB-40AF-BE93-0810D4678775 Q33614632-6680A930-35F7-459F-B67A-2F2377BB7E0C Q33615005-475CED3C-9FD6-4A91-AB28-A5CC4EFFC775 Q33668052-960035F1-AA27-402C-AE07-2CC04FC360C6 Q33746550-C3B21946-A80B-4BA5-B6FC-2AD2B0967BB5 Q33766033-C066C917-DD9F-400A-995E-5C164CC0EA4A Q33791008-0C88535F-4EC8-47B0-B191-BBCF8C61AED6 Q33810342-E6A38314-B909-4FFB-8ED5-E8A2427845DB Q33811917-48734582-5AC5-4E0D-9AEA-532B2A4DE0E1 Q33862420-469C5BCC-B7D8-4653-A879-827D7FD4AF86 Q33876257-772BE817-F3F1-46CC-83A6-63AE56575F6A Q33876492-ABCD5B98-8360-4FDE-989F-1547B3CE37D4 Q33903600-80CBAA74-FDD4-45B3-9990-A7964FC7E828 Q34316593-54BEFF8A-D261-425A-85AF-B5E8C573A276 Q34351611-D7674B3E-734C-400F-AA59-DF71232596B7 Q34422576-FC441D8C-4505-4BE9-8B97-CAD10E0F4A50 Q35872435-A050D3B9-9519-4934-8C42-F6673C9D25D0 Q36610755-50E9883F-C392-4F72-A6E4-DCC2A456CB25 Q37501304-5BB5D864-BA74-4A54-BE64-618B2183B449 Q37862224-A61BD989-7B15-4B48-9C6E-868E4F5618B7 Q38960185-CCF55B4F-ACBD-4434-8ED3-93CA96C452AB Q39482778-32DC3EDA-7721-42FF-A048-09BD15473483 Q41426709-576FD413-6E5A-441F-A31C-94A43920A12A Q41932456-D0B7EC27-5259-4AE2-BD23-BAC39A16F964 Q41980724-8B839F9B-7086-492C-B5E5-827A26A87B4D Q43414532-E9166117-F0B0-4BA0-AA2D-14F29F2440F4 Q44999449-E0A9F104-FAA6-4DCF-82DD-CB948D78AB31 Q45330213-50605C4B-55BD-46C7-BC3A-11FB88747042 Q45961690-6249F444-EC7D-4B23-9909-96A077ADEE56 Q45961735-1E3A9062-97DB-4BF9-A57C-EC03DB9F1883 Q46159949-BC95B0B1-907B-4E21-BE91-DC7EB46E4D97 Q47197241-8239312A-B9DD-4457-A4FB-48D61B436596 Q47278490-C1B9EA59-4DFD-4218-B37B-DD3DE81E3A19

P2860

Structure-based and ligand-based drug design for HER 2 receptor.

http://www.wikidata.org/entity/Q43061745

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Structure-based and ligand-based drug design for HER 2 receptor.

@en

Structure-based and ligand-based drug design for HER 2 receptor.

@nl

type

label

Structure-based and ligand-based drug design for HER 2 receptor.

@en

Structure-based and ligand-based drug design for HER 2 receptor.

@nl

prefLabel

Structure-based and ligand-based drug design for HER 2 receptor.

@en

Structure-based and ligand-based drug design for HER 2 receptor.

@nl

P1433

Q43061745-E84C98F2-9A75-41D4-80F3-5C1380B8D3C4

P1476

Q43061745-1873C896-71E1-4956-B7BE-F7B8AF6D2B31

P2093

Q43061745-12965855-BFEE-4A08-9D3F-AED5820B2082

Q43061745-660B13A5-90A9-4A03-804A-4EF60C932960

Q43061745-75D89700-36CA-46FD-8860-8349D7A9238A

Q43061745-7668891E-3E53-413F-922F-466E2251773C

Q43061745-79A6B352-8A8B-48A9-BF0C-0E6A817C70F2

Q43061745-A84657DD-01E5-465E-AED9-F61115D2D71D

Q43061745-B9E89357-E085-48E6-962E-B482D05A0C5F

Q43061745-C31925FC-FBDC-456D-9AD2-9B51E56D5C5A

P2860

Q43061745-008A5FA2-55F7-4B9C-8826-00E6C62971DD

Q43061745-0B79A78F-5283-49CF-9447-AC1AC8CCAAF0

Q43061745-10D7F435-0C12-468C-9141-098844F08256

Q43061745-2426AF22-1D8A-4C8A-BA5D-4006A7579107

Q43061745-24D3AA41-1A00-405E-8B0D-D5E5F2ADD0C4

Q43061745-2BF25099-2671-462F-ACDC-310C3E55B707

Q43061745-2F5FC054-0A87-4277-BA71-1ED8A758BB64

Q43061745-395B029C-8CB1-42BF-863B-AA9D3C19F90B

Q43061745-47E50F08-A3DF-4824-9FC0-AA4E3719AA2A

Q43061745-4E881C8C-3EFD-4391-835B-C0D7D97BB886

P304

Q43061745-1116C03F-A635-4968-8E3A-0725AEF26FFB

P31

Q43061745-1ACFBC33-B9C8-411C-A91A-4F1724C20042

P356

Q43061745-D79F0B9C-AC0C-4305-A210-99C4E372B9E8

P433

Q43061745-C7D3D365-0CAE-49EA-BA87-C07AB5D8D713

P478

Q43061745-E92421D7-C908-4305-984E-04809F39A24F

P577

Q43061745-4A8C1CD0-9C91-491A-8C3E-3E247D0A8591

P698

Q43061745-62C2D38A-42B9-4737-A379-48B1719D31A1

P356

07391102.2010.10507341

P1433

Journal of Biomolecular Structure and Dynamics

P1476

Structure-based and ligand-based drug design for HER 2 receptor.

@en

P2093

Calvin Yu-Chian Chen

http://www.w3.org/2001/XMLSchema#string

Chien-Yu Chen

http://www.w3.org/2001/XMLSchema#string

Chih-Ho Hsu

http://www.w3.org/2001/XMLSchema#string

Fuu-Jen Tsai

http://www.w3.org/2001/XMLSchema#string

Hsin W Yu

http://www.w3.org/2001/XMLSchema#string

Hsin-Yi Chen

http://www.w3.org/2001/XMLSchema#string

Hung-Jin Huang

http://www.w3.org/2001/XMLSchema#string

Kuei-Jen Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

HER2/neu in systemic therapy for women with breast cancer: a systematic review.

Molecular dynamics simulations to gain insights into the stability and morphologies of K3 oligomers from beta2-microglobulin.

Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis.

Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.

Tyrosine kinase activation in the decision between growth, differentiation, and death responses initiated from the B cell antigen receptor.

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.

P304

23-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07391102.2010.10507341

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20476793

http://www.w3.org/2001/XMLSchema#string